Summary

The global Medical Topical Hemostatic Agent market is projected to grow from US$ 3507 million in 2025 to US$ 5972 million by 2032, at a CAGR of 8.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Medical Topical Hemostatic Agents refer to locally applied medical products designed to control bleeding at the site of tissue injury, surgical intervention, endoscopic treatment, trauma, or other invasive procedures by accelerating clot formation, absorbing blood, concentrating coagulation components, providing a physical barrier, adhering to tissue, or forming a sealing matrix. Commercial Topical Hemostatic Agents are available in multiple product forms, including absorbable sponges, gauze, powders, particles, patches, flowable matrices, gels, hydrogels, fibrin-based preparations, collagen-based materials, oxidized cellulose products, polysaccharide materials, mineral-based agents, and other bioabsorbable or biologically active formulations. Product performance is generally evaluated through time to hemostasis, ability to control diffuse or difficult bleeding, tissue adherence, absorption characteristics, biocompatibility, resorption profile, ease of application, compatibility with minimally invasive delivery systems, and storage stability. This research focuses on finished Topical Hemostatic Agents used for local bleeding control across surgical, endoscopic, procedural, and trauma-related applications and evaluates the market from the perspectives of material technology, product form, clinical application, regional demand, industry chain, sales channels, and competitive structure.
Key Findings
Medical Topical Hemostatic Agents combine passive, active, biologic, and advanced biomaterial-based approaches to achieve localized bleeding control
Powders, sponges, matrices, patches, sealants, and hydrogels form the principal commercial product formats
Clinical demand increasingly favors rapid hemostasis, broad-surface coverage, tissue adherence, and ease of minimally invasive delivery
Product differentiation is increasingly driven by material technology, resorption profile, biocompatibility, and procedural efficiency
The market serves surgery, endoscopy, trauma care, interventional procedures, and other local bleeding-control applications
Market Trends
The Medical Topical Hemostatic Agents industry is evolving from conventional passive absorbable materials toward more advanced products that combine rapid blood absorption, active coagulation support, tissue adhesion, barrier formation, and controlled biodegradation. Traditional gelatin, collagen, oxidized cellulose, and related absorbable products continue to serve broad surgical needs, while flowable matrices, hemostatic powders, fibrin-based products, polysaccharide systems, self-assembling hydrogels, and adhesive biomaterials are expanding the range of available treatment mechanisms. Product development increasingly focuses on faster and more predictable hemostasis, improved performance on irregular or difficult-to-access bleeding surfaces, reduced swelling, lower foreign-body response, easier application through laparoscopic or endoscopic instruments, and better compatibility with minimally invasive procedures. Another long-term trend is the shift from single-purpose hemostatic materials toward products that combine bleeding control with tissue protection, sealing, wound coverage, or procedural simplification.
Market Dynamics
Drivers
Growth of the Medical Topical Hemostatic Agents market is supported by increasing surgical and interventional procedure volumes, wider adoption of minimally invasive surgery, continued demand for effective management of intraoperative and procedural bleeding, and the expansion of advanced endoscopic and trauma-care capabilities. Conventional sutures, clips, electrocautery, and manual compression are not optimal for every bleeding situation, particularly diffuse oozing, friable tissue, complex anatomical locations, or patients with impaired coagulation. Medical Topical Hemostatic Agents therefore provide complementary tools that can reduce time spent achieving local bleeding control and support more standardized procedural workflows. The recurring use of disposable hemostatic products across hospitals and surgical centers also creates a stable consumption-based demand structure.
Restraints
Market development is constrained by purchasing-price pressure, reimbursement differences, strong competition from established mechanical and energy-based hemostasis techniques, and variations in clinical preference between surgeons and institutions. Advanced matrices, biologic sealants, and specialized powders can carry considerably higher acquisition costs than conventional absorbable materials, requiring manufacturers to demonstrate clear clinical and procedural value. Certain products may also present limitations related to swelling, tissue adhesion, preparation requirements, application complexity, storage conditions, or suitability for specific bleeding severities. Strict regulatory, sterility, biocompatibility, viral-safety, and manufacturing-quality requirements further increase development and production costs, particularly for biologic and combination products.
Opportunities
Future opportunities are concentrated in minimally invasive surgery, robotic surgery, advanced gastrointestinal endoscopy, complex cardiovascular and orthopedic procedures, trauma management, and next-generation biomaterial platforms. Products capable of delivering rapid hemostasis through narrow applicators or catheters, covering irregular surfaces, remaining effective in wet environments, and degrading predictably after treatment can address important procedural needs. Additional opportunities exist in plant-derived materials, synthetic peptides, advanced polysaccharides, bioadhesive polymers, and combination technologies designed to reduce reliance on human- or animal-derived components. Manufacturers can also expand through broader procedural indications, new delivery devices, localized production, and partnerships with surgical or endoscopy equipment companies.
Challenges
The principal challenge for Medical Topical Hemostatic Agents is achieving reproducible performance across different bleeding intensities, tissue types, anatomical environments, and clinical techniques. Products effective for capillary or diffuse venous oozing may not provide definitive control of severe arterial bleeding, requiring careful indication positioning and integration with conventional hemostatic methods. Manufacturers must balance rapid hemostatic action with safety factors such as swelling, embolization risk, tissue reaction, infection control, biodegradation, and removal or resorption characteristics. Clinical evidence requirements, product-specific training, differences in hospital procurement criteria, and country-specific regulatory pathways further complicate commercialization and make sustained market adoption dependent on both technical performance and demonstrated procedural value.
Industry Chain Analysis
The upstream segment of the Medical Topical Hemostatic Agents industry includes gelatin, collagen, oxidized cellulose, polysaccharides, mineral absorbents, fibrinogen and thrombin components, synthetic polymers, peptides, chitosan, cellulose derivatives, medical-grade excipients, adhesives, and other functional biomaterials. It also includes supporting materials such as sterile water, buffers, stabilizers, carriers, syringes, applicators, catheters, cartridges, mesh substrates, packaging films, and sterile barrier systems. Raw-material purity, biological origin, molecular consistency, particle characteristics, absorption behavior, endotoxin control, and sterilization compatibility directly influence final product quality and regulatory requirements.
The midstream stage covers biomaterial processing, formulation, coating, powder engineering, sponge or patch fabrication, gel or matrix preparation, aseptic filling, device integration, sterilization, packaging, quality testing, and product release. Value creation is concentrated in material science, formulation know-how, delivery-system design, manufacturing consistency, clinical validation, and regulatory compliance. Downstream customers include hospitals, ambulatory surgery centers, specialty clinics, endoscopy centers, trauma-care providers, and other procedural healthcare institutions. Large healthcare systems generally rely on direct contracts, tenders, or group purchasing organizations, while regional distributors remain important for fragmented markets. Industry profitability therefore depends on technology differentiation, production efficiency, clinical evidence, regulatory approvals, procedure-level economics, and access to surgical and interventional sales channels.
Segment Insights
Medical Topical Hemostatic Agents can be segmented by material and mechanism into passive absorbable agents, biologically active agents, flowable matrices, sealants, powders, and advanced biomaterial-based products. Conventional gelatin, collagen, and oxidized cellulose products remain important because of their established clinical use, relatively simple handling, and broad surgical applicability. Biologically active products containing coagulation-related components provide a different mechanism by directly supporting clot formation, while flowable matrices and powders are better suited to irregular surfaces, cavities, diffuse bleeding, and locations where traditional sheet-form products are difficult to position.
Advanced segments are increasingly differentiated by the ability to combine rapid hemostasis with tissue adhesion, controlled degradation, minimized swelling, broad-surface coverage, and minimally invasive delivery. Synthetic and plant-derived technologies also provide opportunities to reduce dependence on animal- or human-derived materials. Rather than converging toward a single dominant technology, the market is likely to maintain a multi-platform structure because product selection varies substantially by procedure type, bleeding severity, anatomical location, physician preference, and treatment cost.
Downstream Market Opportunities
Downstream opportunities for Medical Topical Hemostatic Agents are concentrated in surgical specialties and procedures where rapid, localized, and reliable bleeding control can improve workflow efficiency. Cardiovascular surgery, general surgery, orthopedic surgery, neurosurgery, gynecology, urology, gastrointestinal endoscopy, trauma care, and other minimally invasive procedures create different requirements for product form and mechanism. Hospitals increasingly value agents that are ready to use, easy to apply, compatible with laparoscopic or endoscopic devices, and capable of treating irregular or difficult-to-access surfaces. As procedure complexity increases, manufacturers that can demonstrate shorter time to hemostasis, lower reintervention requirements, simplified preparation, predictable resorption, and favorable procedure-level economics can obtain stronger downstream adoption.
Regional Insights
North America and Europe are mature commercial regions for Medical Topical Hemostatic Agents, supported by high surgical procedure volumes, developed hospital infrastructure, broad availability of advanced surgical technologies, and established use of absorbable hemostats, flowable matrices, sealants, and other specialty products. Procurement decisions in these markets increasingly consider clinical evidence, procedure efficiency, reimbursement conditions, surgeon familiarity, supply reliability, and total treatment cost rather than product price alone. Regulatory requirements and hospital purchasing standards also create relatively high barriers to market entry.
Asia-Pacific represents an important expansion area as surgical capacity, minimally invasive procedures, endoscopic treatment, and domestic medical-device manufacturing continue to develop. China, Japan, South Korea, and other Asian healthcare markets display different levels of adoption and local manufacturing capability, creating opportunities for both multinational and regional suppliers. Latin America, the Middle East, and Africa also provide longer-term growth potential as access to surgery and advanced procedural care improves, although reimbursement, hospital budgets, product registration, and distributor coverage can lead to substantial differences in product mix and pricing between countries.
Competitive Landscape Analysis
The Medical Topical Hemostatic Agents market has a diversified competitive structure involving large multinational medical-device companies, biosurgery specialists, biomaterials manufacturers, blood-product companies, and regional producers. Established participants compete through broad surgical portfolios, hospital relationships, clinical evidence, regulatory approvals, and global distribution capabilities, while specialist manufacturers differentiate through proprietary materials such as polysaccharide powders, fibrin systems, synthetic peptides, chitosan, collagen, gelatin, oxidized cellulose, mineral absorbents, and advanced adhesive polymers. Competition is therefore not based on a single standardized product platform; instead, companies occupy different positions according to mechanism of action, product form, surgical specialty, delivery technology, and price level. As hospitals increasingly evaluate products on procedure-level value, competitive advantage is shifting toward faster and more reliable hemostasis, simplified preparation, minimally invasive delivery, favorable safety and resorption characteristics, manufacturing consistency, clinical support, and the ability to offer a broader portfolio across multiple surgical applications.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Medical Topical Hemostatic Agent market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Ethicon
Baxter
BD
Pfizer
Corza Medical
Grifols
B. Braun
Integra
Teleflex
BioLife
CuraMedical
GELITA MEDICAL
Grena Biomed
3-D Matrix
Cook Medical
EndoClot Plus
NEXT Biomedical
BioCer
Tricol Biomedical
Celox Medical
Singclean
Qingdao Zhonghuishengxi
Bioseal
Segment by Type
Passive Hemostatic Agents
Active Hemostatic Agents
Segment by Material Composition
Gelatin-Based Hemostatic Agents
Collagen-Based Hemostatic Agents
Polysaccharide-Based Hemostatic Agents
Other
Segment by Product Form
Liquid / Spray Hemostat
Hemostatic Gel / Hydrogel
Hemostatic Powder
Other
Segment by Application
Hospitals
Surgical Centers
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Medical Topical Hemostatic Agent study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Medical Topical Hemostatic Agent: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Medical Topical Hemostatic Agent Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Passive Hemostatic Agents
1.2.3 Active Hemostatic Agents
1.3 Market Segmentation by Material Composition
1.3.1 Global Medical Topical Hemostatic Agent Market Size by Material Composition, 2021 vs 2025 vs 2032
1.3.2 Gelatin-Based Hemostatic Agents
1.3.3 Collagen-Based Hemostatic Agents
1.3.4 Polysaccharide-Based Hemostatic Agents
1.3.5 Other
1.4 Market Segmentation by Product Form
1.4.1 Global Medical Topical Hemostatic Agent Market Size by Product Form, 2021 vs 2025 vs 2032
1.4.2 Liquid / Spray Hemostat
1.4.3 Hemostatic Gel / Hydrogel
1.4.4 Hemostatic Powder
1.4.5 Other
1.5 Market Segmentation by Application
1.5.1 Global Medical Topical Hemostatic Agent Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospitals
1.5.3 Surgical Centers
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Medical Topical Hemostatic Agent Revenue Estimates and Forecasts (2021-2032)
2.2 Global Medical Topical Hemostatic Agent Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Medical Topical Hemostatic Agent Sales Estimates and Forecasts (2021-2032)
2.4 Global Medical Topical Hemostatic Agent Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Medical Topical Hemostatic Agent Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Medical Topical Hemostatic Agent Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Passive Hemostatic Agents: Market Share by Key Manufacturers
3.5.2 Active Hemostatic Agents: Market Share by Key Manufacturers
3.6 Global Medical Topical Hemostatic Agent Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Medical Topical Hemostatic Agent Sales Performance by Type
4.1.1 Global Medical Topical Hemostatic Agent Sales Volume by Type (2021-2032)
4.1.2 Global Medical Topical Hemostatic Agent Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Medical Topical Hemostatic Agent Sales Performance by Material Composition
4.2.1 Global Medical Topical Hemostatic Agent Sales Volume by Material Composition (2021-2032)
4.2.2 Global Medical Topical Hemostatic Agent Revenue by Material Composition (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Material Composition (2021-2032)
4.3 Global Medical Topical Hemostatic Agent Sales Performance by Product Form
4.3.1 Global Medical Topical Hemostatic Agent Sales Volume by Product Form (2021-2032)
4.3.2 Global Medical Topical Hemostatic Agent Revenue by Product Form (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Product Form (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Medical Topical Hemostatic Agent Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Medical Topical Hemostatic Agent Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Medical Topical Hemostatic Agent Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Medical Topical Hemostatic Agent Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Medical Topical Hemostatic Agent Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Medical Topical Hemostatic Agent Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Medical Topical Hemostatic Agent Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Medical Topical Hemostatic Agent Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Medical Topical Hemostatic Agent Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Medical Topical Hemostatic Agent Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Medical Topical Hemostatic Agent Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Medical Topical Hemostatic Agent Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Ethicon
11.1.1 Ethicon Corporation Information
11.1.2 Ethicon Business Overview
11.1.3 Ethicon Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.1.4 Ethicon Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Ethicon Medical Topical Hemostatic Agent Sales by Product in 2025
11.1.6 Ethicon Medical Topical Hemostatic Agent Sales by Application in 2025
11.1.7 Ethicon Medical Topical Hemostatic Agent Sales by Geographic Area in 2025
11.1.8 Ethicon Medical Topical Hemostatic Agent SWOT Analysis
11.1.9 Ethicon Recent Developments
11.2 Baxter
11.2.1 Baxter Corporation Information
11.2.2 Baxter Business Overview
11.2.3 Baxter Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.2.4 Baxter Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Baxter Medical Topical Hemostatic Agent Sales by Product in 2025
11.2.6 Baxter Medical Topical Hemostatic Agent Sales by Application in 2025
11.2.7 Baxter Medical Topical Hemostatic Agent Sales by Geographic Area in 2025
11.2.8 Baxter Medical Topical Hemostatic Agent SWOT Analysis
11.2.9 Baxter Recent Developments
11.3 BD
11.3.1 BD Corporation Information
11.3.2 BD Business Overview
11.3.3 BD Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.3.4 BD Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 BD Medical Topical Hemostatic Agent Sales by Product in 2025
11.3.6 BD Medical Topical Hemostatic Agent Sales by Application in 2025
11.3.7 BD Medical Topical Hemostatic Agent Sales by Geographic Area in 2025
11.3.8 BD Medical Topical Hemostatic Agent SWOT Analysis
11.3.9 BD Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.4.4 Pfizer Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Pfizer Medical Topical Hemostatic Agent Sales by Product in 2025
11.4.6 Pfizer Medical Topical Hemostatic Agent Sales by Application in 2025
11.4.7 Pfizer Medical Topical Hemostatic Agent Sales by Geographic Area in 2025
11.4.8 Pfizer Medical Topical Hemostatic Agent SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 Corza Medical
11.5.1 Corza Medical Corporation Information
11.5.2 Corza Medical Business Overview
11.5.3 Corza Medical Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.5.4 Corza Medical Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Corza Medical Medical Topical Hemostatic Agent Sales by Product in 2025
11.5.6 Corza Medical Medical Topical Hemostatic Agent Sales by Application in 2025
11.5.7 Corza Medical Medical Topical Hemostatic Agent Sales by Geographic Area in 2025
11.5.8 Corza Medical Medical Topical Hemostatic Agent SWOT Analysis
11.5.9 Corza Medical Recent Developments
11.6 Grifols
11.6.1 Grifols Corporation Information
11.6.2 Grifols Business Overview
11.6.3 Grifols Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.6.4 Grifols Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Grifols Recent Developments
11.7 B. Braun
11.7.1 B. Braun Corporation Information
11.7.2 B. Braun Business Overview
11.7.3 B. Braun Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.7.4 B. Braun Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 B. Braun Recent Developments
11.8 Integra
11.8.1 Integra Corporation Information
11.8.2 Integra Business Overview
11.8.3 Integra Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.8.4 Integra Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Integra Recent Developments
11.9 Teleflex
11.9.1 Teleflex Corporation Information
11.9.2 Teleflex Business Overview
11.9.3 Teleflex Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.9.4 Teleflex Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Teleflex Recent Developments
11.10 BioLife
11.10.1 BioLife Corporation Information
11.10.2 BioLife Business Overview
11.10.3 BioLife Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.10.4 BioLife Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 BioLife Recent Developments
11.11 CuraMedical
11.11.1 CuraMedical Corporation Information
11.11.2 CuraMedical Business Overview
11.11.3 CuraMedical Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.11.4 CuraMedical Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 CuraMedical Recent Developments
11.12 GELITA MEDICAL
11.12.1 GELITA MEDICAL Corporation Information
11.12.2 GELITA MEDICAL Business Overview
11.12.3 GELITA MEDICAL Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.12.4 GELITA MEDICAL Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 GELITA MEDICAL Recent Developments
11.13 Grena Biomed
11.13.1 Grena Biomed Corporation Information
11.13.2 Grena Biomed Business Overview
11.13.3 Grena Biomed Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.13.4 Grena Biomed Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Grena Biomed Recent Developments
11.14 3-D Matrix
11.14.1 3-D Matrix Corporation Information
11.14.2 3-D Matrix Business Overview
11.14.3 3-D Matrix Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.14.4 3-D Matrix Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 3-D Matrix Recent Developments
11.15 Cook Medical
11.15.1 Cook Medical Corporation Information
11.15.2 Cook Medical Business Overview
11.15.3 Cook Medical Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.15.4 Cook Medical Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Cook Medical Recent Developments
11.16 EndoClot Plus
11.16.1 EndoClot Plus Corporation Information
11.16.2 EndoClot Plus Business Overview
11.16.3 EndoClot Plus Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.16.4 EndoClot Plus Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 EndoClot Plus Recent Developments
11.17 NEXT Biomedical
11.17.1 NEXT Biomedical Corporation Information
11.17.2 NEXT Biomedical Business Overview
11.17.3 NEXT Biomedical Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.17.4 NEXT Biomedical Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 NEXT Biomedical Recent Developments
11.18 BioCer
11.18.1 BioCer Corporation Information
11.18.2 BioCer Business Overview
11.18.3 BioCer Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.18.4 BioCer Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 BioCer Recent Developments
11.19 Tricol Biomedical
11.19.1 Tricol Biomedical Corporation Information
11.19.2 Tricol Biomedical Business Overview
11.19.3 Tricol Biomedical Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.19.4 Tricol Biomedical Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Tricol Biomedical Recent Developments
11.20 Celox Medical
11.20.1 Celox Medical Corporation Information
11.20.2 Celox Medical Business Overview
11.20.3 Celox Medical Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.20.4 Celox Medical Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Celox Medical Recent Developments
11.21 Singclean
11.21.1 Singclean Corporation Information
11.21.2 Singclean Business Overview
11.21.3 Singclean Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.21.4 Singclean Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 Singclean Recent Developments
11.22 Qingdao Zhonghuishengxi
11.22.1 Qingdao Zhonghuishengxi Corporation Information
11.22.2 Qingdao Zhonghuishengxi Business Overview
11.22.3 Qingdao Zhonghuishengxi Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.22.4 Qingdao Zhonghuishengxi Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Qingdao Zhonghuishengxi Recent Developments
11.23 Bioseal
11.23.1 Bioseal Corporation Information
11.23.2 Bioseal Business Overview
11.23.3 Bioseal Medical Topical Hemostatic Agent Product Models, Descriptions and Specifications
11.23.4 Bioseal Medical Topical Hemostatic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Bioseal Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Medical Topical Hemostatic Agent Industry Chain
12.2 Medical Topical Hemostatic Agent Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Medical Topical Hemostatic Agent Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Medical Topical Hemostatic Agent Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Medical Topical Hemostatic Agent Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Medical Topical Hemostatic Agent Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Material Composition, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Product Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Medical Topical Hemostatic Agent Revenue by Region (US$ Million), 2021-2026
Table 7. Global Medical Topical Hemostatic Agent Revenue by Region (US$ Million), 2027-2032
Table 8. Global Medical Topical Hemostatic Agent Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Table 9. Global Medical Topical Hemostatic Agent Sales by Region (K Units), 2021-2026
Table 10. Global Medical Topical Hemostatic Agent Sales by Region (K Units), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Medical Topical Hemostatic Agent Sales by Manufacturers (K Units), 2021-2026
Table 13. Global Medical Topical Hemostatic Agent Sales Share by Manufacturers (2021-2026)
Table 14. Global Medical Topical Hemostatic Agent Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Medical Topical Hemostatic Agent Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Medical Topical Hemostatic Agent Revenue, 2025
Table 18. Global Medical Topical Hemostatic Agent Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Medical Topical Hemostatic Agent Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 20. Key Manufacturers Medical Topical Hemostatic Agent Manufacturing Base and Headquarters
Table 21. Global Medical Topical Hemostatic Agent Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Medical Topical Hemostatic Agent Sales Volume by Type (K Units), 2021-2026
Table 25. Global Medical Topical Hemostatic Agent Sales Volume by Type (K Units), 2027-2032
Table 26. Global Medical Topical Hemostatic Agent Revenue by Type (US$ Million), 2021-2026
Table 27. Global Medical Topical Hemostatic Agent Revenue by Type (US$ Million), 2027-2032
Table 28. Global Medical Topical Hemostatic Agent Sales Volume by Material Composition (K Units), 2021-2026
Table 29. Global Medical Topical Hemostatic Agent Sales Volume by Material Composition (K Units), 2027-2032
Table 30. Global Medical Topical Hemostatic Agent Revenue by Material Composition (US$ Million), 2021-2026
Table 31. Global Medical Topical Hemostatic Agent Revenue by Material Composition (US$ Million), 2027-2032
Table 32. Global Medical Topical Hemostatic Agent Sales Volume by Product Form (K Units), 2021-2026
Table 33. Global Medical Topical Hemostatic Agent Sales Volume by Product Form (K Units), 2027-2032
Table 34. Global Medical Topical Hemostatic Agent Revenue by Product Form (US$ Million), 2021-2026
Table 35. Global Medical Topical Hemostatic Agent Revenue by Product Form (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Medical Topical Hemostatic Agent Sales by Application (K Units), 2021-2026
Table 38. Global Medical Topical Hemostatic Agent Sales by Application (K Units), 2027-2032
Table 39. Medical Topical Hemostatic Agent High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Medical Topical Hemostatic Agent Revenue by Application (US$ Million), 2021-2026
Table 41. Global Medical Topical Hemostatic Agent Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Medical Topical Hemostatic Agent Growth Accelerators and Market Barriers
Table 45. North America Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Medical Topical Hemostatic Agent Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Medical Topical Hemostatic Agent Growth Accelerators and Market Barriers
Table 48. Europe Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Medical Topical Hemostatic Agent Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Medical Topical Hemostatic Agent Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Medical Topical Hemostatic Agent Growth Accelerators and Market Barriers
Table 53. Southeast Asia Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Medical Topical Hemostatic Agent Investment Opportunities and Key Challenges
Table 55. Central and South America Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Medical Topical Hemostatic Agent Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Medical Topical Hemostatic Agent Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Ethicon Corporation Information
Table 59. Ethicon Description and Major Businesses
Table 60. Ethicon Product Models, Descriptions and Specifications
Table 61. Ethicon Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 62. Ethicon Sales Value Proportion by Product in 2025
Table 63. Ethicon Sales Value Proportion by Application in 2025
Table 64. Ethicon Sales Value Proportion by Geographic Area in 2025
Table 65. Ethicon Medical Topical Hemostatic Agent SWOT Analysis
Table 66. Ethicon Recent Developments
Table 67. Baxter Corporation Information
Table 68. Baxter Description and Major Businesses
Table 69. Baxter Product Models, Descriptions and Specifications
Table 70. Baxter Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Baxter Sales Value Proportion by Product in 2025
Table 72. Baxter Sales Value Proportion by Application in 2025
Table 73. Baxter Sales Value Proportion by Geographic Area in 2025
Table 74. Baxter Medical Topical Hemostatic Agent SWOT Analysis
Table 75. Baxter Recent Developments
Table 76. BD Corporation Information
Table 77. BD Description and Major Businesses
Table 78. BD Product Models, Descriptions and Specifications
Table 79. BD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. BD Sales Value Proportion by Product in 2025
Table 81. BD Sales Value Proportion by Application in 2025
Table 82. BD Sales Value Proportion by Geographic Area in 2025
Table 83. BD Medical Topical Hemostatic Agent SWOT Analysis
Table 84. BD Recent Developments
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Major Businesses
Table 87. Pfizer Product Models, Descriptions and Specifications
Table 88. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Pfizer Sales Value Proportion by Product in 2025
Table 90. Pfizer Sales Value Proportion by Application in 2025
Table 91. Pfizer Sales Value Proportion by Geographic Area in 2025
Table 92. Pfizer Medical Topical Hemostatic Agent SWOT Analysis
Table 93. Pfizer Recent Developments
Table 94. Corza Medical Corporation Information
Table 95. Corza Medical Description and Major Businesses
Table 96. Corza Medical Product Models, Descriptions and Specifications
Table 97. Corza Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Corza Medical Sales Value Proportion by Product in 2025
Table 99. Corza Medical Sales Value Proportion by Application in 2025
Table 100. Corza Medical Sales Value Proportion by Geographic Area in 2025
Table 101. Corza Medical Medical Topical Hemostatic Agent SWOT Analysis
Table 102. Corza Medical Recent Developments
Table 103. Grifols Corporation Information
Table 104. Grifols Description and Major Businesses
Table 105. Grifols Product Models, Descriptions and Specifications
Table 106. Grifols Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Grifols Recent Developments
Table 108. B. Braun Corporation Information
Table 109. B. Braun Description and Major Businesses
Table 110. B. Braun Product Models, Descriptions and Specifications
Table 111. B. Braun Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. B. Braun Recent Developments
Table 113. Integra Corporation Information
Table 114. Integra Description and Major Businesses
Table 115. Integra Product Models, Descriptions and Specifications
Table 116. Integra Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Integra Recent Developments
Table 118. Teleflex Corporation Information
Table 119. Teleflex Description and Major Businesses
Table 120. Teleflex Product Models, Descriptions and Specifications
Table 121. Teleflex Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Teleflex Recent Developments
Table 123. BioLife Corporation Information
Table 124. BioLife Description and Major Businesses
Table 125. BioLife Product Models, Descriptions and Specifications
Table 126. BioLife Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. BioLife Recent Developments
Table 128. CuraMedical Corporation Information
Table 129. CuraMedical Description and Major Businesses
Table 130. CuraMedical Product Models, Descriptions and Specifications
Table 131. CuraMedical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. CuraMedical Recent Developments
Table 133. GELITA MEDICAL Corporation Information
Table 134. GELITA MEDICAL Description and Major Businesses
Table 135. GELITA MEDICAL Product Models, Descriptions and Specifications
Table 136. GELITA MEDICAL Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. GELITA MEDICAL Recent Developments
Table 138. Grena Biomed Corporation Information
Table 139. Grena Biomed Description and Major Businesses
Table 140. Grena Biomed Product Models, Descriptions and Specifications
Table 141. Grena Biomed Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Grena Biomed Recent Developments
Table 143. 3-D Matrix Corporation Information
Table 144. 3-D Matrix Description and Major Businesses
Table 145. 3-D Matrix Product Models, Descriptions and Specifications
Table 146. 3-D Matrix Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. 3-D Matrix Recent Developments
Table 148. Cook Medical Corporation Information
Table 149. Cook Medical Description and Major Businesses
Table 150. Cook Medical Product Models, Descriptions and Specifications
Table 151. Cook Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Cook Medical Recent Developments
Table 153. EndoClot Plus Corporation Information
Table 154. EndoClot Plus Description and Major Businesses
Table 155. EndoClot Plus Product Models, Descriptions and Specifications
Table 156. EndoClot Plus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. EndoClot Plus Recent Developments
Table 158. NEXT Biomedical Corporation Information
Table 159. NEXT Biomedical Description and Major Businesses
Table 160. NEXT Biomedical Product Models, Descriptions and Specifications
Table 161. NEXT Biomedical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. NEXT Biomedical Recent Developments
Table 163. BioCer Corporation Information
Table 164. BioCer Description and Major Businesses
Table 165. BioCer Product Models, Descriptions and Specifications
Table 166. BioCer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. BioCer Recent Developments
Table 168. Tricol Biomedical Corporation Information
Table 169. Tricol Biomedical Description and Major Businesses
Table 170. Tricol Biomedical Product Models, Descriptions and Specifications
Table 171. Tricol Biomedical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Tricol Biomedical Recent Developments
Table 173. Celox Medical Corporation Information
Table 174. Celox Medical Description and Major Businesses
Table 175. Celox Medical Product Models, Descriptions and Specifications
Table 176. Celox Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Celox Medical Recent Developments
Table 178. Singclean Corporation Information
Table 179. Singclean Description and Major Businesses
Table 180. Singclean Product Models, Descriptions and Specifications
Table 181. Singclean Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. Singclean Recent Developments
Table 183. Qingdao Zhonghuishengxi Corporation Information
Table 184. Qingdao Zhonghuishengxi Description and Major Businesses
Table 185. Qingdao Zhonghuishengxi Product Models, Descriptions and Specifications
Table 186. Qingdao Zhonghuishengxi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Qingdao Zhonghuishengxi Recent Developments
Table 188. Bioseal Corporation Information
Table 189. Bioseal Description and Major Businesses
Table 190. Bioseal Product Models, Descriptions and Specifications
Table 191. Bioseal Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 192. Bioseal Recent Developments
Table 193. Key Raw Materials Distribution
Table 194. Raw Materials Key Suppliers
Table 195. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 196. Milestones in Production Technology Evolution
Table 197. Distributors List
Table 198. Market Trends and Market Evolution
Table 199. Market Drivers and Opportunities
Table 200. Market Challenges, Risks, and Restraints
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources

List of Figures
Figure 1. Medical Topical Hemostatic Agent Product Picture
Figure 2. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Passive Hemostatic Agents Product Picture
Figure 4. Active Hemostatic Agents Product Picture
Figure 5. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Material Composition, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Gelatin-Based Hemostatic Agents Product Picture
Figure 7. Collagen-Based Hemostatic Agents Product Picture
Figure 8. Polysaccharide-Based Hemostatic Agents Product Picture
Figure 9. Other Product Picture
Figure 10. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Product Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Liquid / Spray Hemostat Product Picture
Figure 12. Hemostatic Gel / Hydrogel Product Picture
Figure 13. Hemostatic Powder Product Picture
Figure 14. Other Product Picture
Figure 15. Global Medical Topical Hemostatic Agent Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Hospitals
Figure 17. Surgical Centers
Figure 18. Other
Figure 19. Medical Topical Hemostatic Agent Report Years Considered
Figure 20. Global Medical Topical Hemostatic Agent Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 22. Global Medical Topical Hemostatic Agent Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Medical Topical Hemostatic Agent Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Medical Topical Hemostatic Agent Sales (K Units), 2021-2032
Figure 25. Global Medical Topical Hemostatic Agent Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Figure 26. Global Medical Topical Hemostatic Agent Sales Market Share by Region (2021-2032)
Figure 27. Top 5 and Top 10 Manufacturers Medical Topical Hemostatic Agent Sales Volume Market Share in 2025
Figure 28. Global Medical Topical Hemostatic Agent Revenue-Based Market Share Ranking (2025)
Figure 29. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 30. Passive Hemostatic Agents Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Active Hemostatic Agents Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Global Medical Topical Hemostatic Agent Sales Volume-Based Market Share by Type (2021-2032)
Figure 33. Global Medical Topical Hemostatic Agent Revenue-Based Market Share by Type (2021-2032)
Figure 34. Global Medical Topical Hemostatic Agent ASP by Type (US$/Unit), 2021-2032
Figure 35. Global Medical Topical Hemostatic Agent Sales Volume-Based Market Share by Material Composition (2021-2032)
Figure 36. Global Medical Topical Hemostatic Agent Revenue-Based Market Share by Material Composition (2021-2032)
Figure 37. Global Medical Topical Hemostatic Agent ASP by Material Composition (US$/Unit), 2021-2032
Figure 38. Global Medical Topical Hemostatic Agent Sales Volume-Based Market Share by Product Form (2021-2032)
Figure 39. Global Medical Topical Hemostatic Agent Revenue-Based Market Share by Product Form (2021-2032)
Figure 40. Global Medical Topical Hemostatic Agent ASP by Product Form (US$/Unit), 2021-2032
Figure 41. Global Medical Topical Hemostatic Agent Sales Market Share by Application (2021-2032)
Figure 42. Global Medical Topical Hemostatic Agent Revenue-Based Market Share by Application (2021-2032)
Figure 43. Global Medical Topical Hemostatic Agent ASP by Application (US$/Unit), 2021-2032
Figure 44. North America Medical Topical Hemostatic Agent Sales YoY (K Units), 2021-2032
Figure 45. North America Medical Topical Hemostatic Agent Revenue YoY (US$ Million), 2021-2032
Figure 46. North America Top 5 Manufacturers Medical Topical Hemostatic Agent Sales Revenue (US$ Million) in 2025
Figure 47. North America Medical Topical Hemostatic Agent Sales Volume (K Units) by Application (2021-2032)
Figure 48. North America Medical Topical Hemostatic Agent Sales Revenue (US$ Million) by Application (2021-2032)
Figure 49. US Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 50. Canada Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 51. Mexico Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 52. Europe Medical Topical Hemostatic Agent Sales YoY (K Units), 2021-2032
Figure 53. Europe Medical Topical Hemostatic Agent Revenue YoY (US$ Million), 2021-2032
Figure 54. Europe Top 5 Manufacturers Medical Topical Hemostatic Agent Sales Revenue (US$ Million) in 2025
Figure 55. Europe Medical Topical Hemostatic Agent Sales Volume (K Units) by Application (2021-2032)
Figure 56. Europe Medical Topical Hemostatic Agent Sales Revenue (US$ Million) by Application (2021-2032)
Figure 57. Germany Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 58. France Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 59. U.K. Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 60. Italy Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 61. Russia Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 62. Asia-Pacific Medical Topical Hemostatic Agent Sales YoY (K Units), 2021-2032
Figure 63. Asia-Pacific Medical Topical Hemostatic Agent Revenue YoY (US$ Million), 2021-2032
Figure 64. Asia-Pacific Top 8 Manufacturers Medical Topical Hemostatic Agent Sales Revenue (US$ Million) in 2025
Figure 65. Asia-Pacific Medical Topical Hemostatic Agent Sales Volume (K Units) by Application (2021-2032)
Figure 66. Asia-Pacific Medical Topical Hemostatic Agent Sales Revenue (US$ Million) by Application (2021-2032)
Figure 67. Indonesia Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 68. Japan Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 69. South Korea Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 70. China Taiwan Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 71. India Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 72. Central and South America Medical Topical Hemostatic Agent Sales YoY (K Units), 2021-2032
Figure 73. Central and South America Medical Topical Hemostatic Agent Revenue YoY (US$ Million), 2021-2032
Figure 74. Central and South America Top 5 Manufacturers Medical Topical Hemostatic Agent Sales Revenue (US$ Million) in 2025
Figure 75. Central and South America Medical Topical Hemostatic Agent Sales Volume (K Units) by Application (2021-2032)
Figure 76. Central and South America Medical Topical Hemostatic Agent Sales Revenue (US$ Million) by Application (2021-2032)
Figure 77. Brazil Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 78. Argentina Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 79. Middle East, and Africa Medical Topical Hemostatic Agent Sales YoY (K Units), 2021-2032
Figure 80. Middle East and Africa Medical Topical Hemostatic Agent Revenue YoY (US$ Million), 2021-2032
Figure 81. Middle East and Africa Top 5 Manufacturers Medical Topical Hemostatic Agent Sales Revenue (US$ Million) in 2025
Figure 82. Middle East and Africa Medical Topical Hemostatic Agent Sales Volume (K Units) by Application (2021-2032)
Figure 83. Middle East and Africa Medical Topical Hemostatic Agent Sales Revenue (US$ Million) by Application (2021-2032)
Figure 84. GCC Countries Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 85. Turkey Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 86. Egypt Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 87. South Africa Medical Topical Hemostatic Agent Revenue (US$ Million), 2021-2032
Figure 88. Medical Topical Hemostatic Agent Industry Chain Mapping
Figure 89. Regional Medical Topical Hemostatic Agent Manufacturing Base Distribution (%)
Figure 90. Global Medical Topical Hemostatic Agent Production Market Share by Region (2021-2032)
Figure 91. Medical Topical Hemostatic Agent Production Process
Figure 92. Regional Medical Topical Hemostatic Agent Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed